Cargando…
Comparison of continuous measures across diagnostic PD-L1 assays in non-small cell lung cancer using automated image analysis
Tumor programmed cell death ligand-1 (PD-L1) expression is a key biomarker to identify patients with non-small cell lung cancer who may have an enhanced response to anti-programmed cell death-1 (PD-1)/PD-L1 treatment. Such treatments are used in conjunction with PD-L1 diagnostic immunohistochemistry...
Autores principales: | Widmaier, Moritz, Wiestler, Tobias, Walker, Jill, Barker, Craig, Scott, Marietta L., Sekhavati, Farzad, Budco, Alexei, Schneider, Katrin, Segerer, Felix J., Steele, Keith, Rebelatto, Marlon C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group US
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7051919/ https://www.ncbi.nlm.nih.gov/pubmed/31527709 http://dx.doi.org/10.1038/s41379-019-0349-y |
Ejemplares similares
-
Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy
por: Althammer, Sonja, et al.
Publicado: (2019) -
Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay
por: Scorer, Paul, et al.
Publicado: (2018) -
Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma
por: Zajac, Magdalena, et al.
Publicado: (2019) -
Deep Semi Supervised Generative Learning for Automated Tumor Proportion Scoring on NSCLC Tissue Needle Biopsies
por: Kapil, Ansh, et al.
Publicado: (2018) -
Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma
por: Rebelatto, Marlon C., et al.
Publicado: (2016)